非高剂量甲氨蝶呤方案OGS-12治疗非转移性骨肉瘤的结局
本研究前瞻性纳入237例初治非转移性肢体骨肉瘤患者,采用不含高剂量甲氨蝶呤的剂量密集方案OGS-12(多柔比星、顺铂、异环磷酰胺序贯双药组合)。中位随访34.31个月,意向性分析5年无事件生存率和总生存率分别为56%和75%,方案毒性可接受,结论认为该方案结局与国际标准相当。
要点
- OGS-12为不含高剂量甲氨蝶呤的剂量密集方案,由多柔比星、顺铂和异环磷酰胺序贯双药组合构成。
- 237例初治非转移性肢体骨肉瘤患者中,意向性分析5年EFS为56%、OS为75%。
- 组织学反应是EFS和OS的独立预测因素,58%可评估患者获得良好反应(活细胞≤10%)。
核心结论
- 在初治非转移性骨肉瘤患者中,OGS-12方案产生与国际标准相当的结局,毒性可接受,值得更广泛的临床应用。
研究设计与样本
- 前瞻性研究,2011年至2014年共纳入317例初治骨肉瘤患者,其中237例(75%)为非转移性肢体骨肉瘤。
- 所有患者接受OGS-12方案,包含多柔比星、顺铂和异环磷酰胺各四疗程,以双药序贯组合形式在新辅助和辅助设置中给药。
- 前瞻性收集基线特征、新辅助化疗组织学反应、毒性、无事件生存期(EFS)和总生存期(OS)数据。
主要发现
- 237例患者中,平均肿瘤大小10.45 cm,71%血清乳酸脱氢酶升高,88%血清碱性磷酸酶升高,34%存在营养挑战。
- 中位随访34.31个月(范围2-60个月),意向性分析5年EFS为56%、OS为75%;符合方案分析分别为60%和80%。
- 发热性中性粒细胞减少发生率为56%,3/4级血小板减少为22%,贫血为47%,发生两例化疗毒性死亡。
- 10%患者出现3/4级腹泻和口腔炎,一例患者发生需透析的4级急性肾损伤。
临床怎么用
- OGS-12方案为不含高剂量甲氨蝶呤的剂量密集方案,经济且易于给药,适合资源受限环境。
- 该方案在初治非转移性骨肉瘤中产生与国际标准相当的5年EFS和OS,毒性可接受。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: High-dose methotrexate (HDMTX)-based regimens are widely used in osteosarcoma. However, mandatory in-patient treatment with complex pharmacokinetic monitoring requirement precludes its use, especially in resource-constrained settings of low- and middle-income countries (LMICs). METHODS: All treatment naive consecutive patients of osteosarcoma were prospectively treated on a novel institutional regimen (named OGS-12) comprising of eight sequential doublets of the following drugs: doxorubicin, cisplatin and ifosfamide in four courses each, given in the neoadjuvant and adjuvant settings. Data were prospectively collected on baseline characteristics, histological response to neoadjuvant chemotherapy (NACT), toxicity, event-free survival (EFS) and overall survival (OS). RESULTS: Between 2011 and 2014, 317 treatment naive patients with extremity osteosarcoma were seen, of whom 237 (75%) were non-metastatic. Majority had high tumour burden, with mean tumour size of 10.45 cm, high serum lactate dehydrogenase (LDH) and serum alkaline phosphatase (SAP) in 71% and 88% respectively. A significant number (34%) were nutritionally challenged. Two-hundred ten of 237 patients were analysable for histological response of which 58% had good response (viable cells ≤10%). At the median follow-up of 34.31 (2-60) months, in intention-to-treat (ITT) analysis, the 5-year EFS and OS were 56% and 75% respectively; the same were 60% and 80% in per-protocol analysis. There was febrile neutropenia (FN) in 56%, grade 3/4 thrombocytopaenia in 22% and anaemia in 47% with two chemotoxic deaths. Ten percent of the patients had grade 3/4 diarrhoea and stomatitis and one patient developed grade 4 acute kidney injury requiring dialysis. Baseline SAP (per-protocol) for EFS and performance status (ITT) for OS were found to be independent variables. Histological response was an independent predictor for EFS and OS in both the analyses. CONCLUSIONS: In treatment naive patients with non-metastatic osteosarcoma, OGS-12 protocol, a dose-dense, non-HDMTX-based, novel, economic and easy to administer regimen produces comparable outcomes to international standards, with acceptable toxicity and is worthy of wider clinical application.
引用
- Bajpai J, Chandrasekharan A, Talreja V, et al. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'. Eur J Cancer. 2017. PMID: 28888849. doi:10.1016/j.ejca.2017.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。